促炎性CD20+ T细胞受多发性硬化疗法差异化影响
多发性硬化患者中CD20+ T细胞呈促炎致病表型。抗CD20治疗几乎清除该细胞,富马酸二甲酯抑制其活性,芬戈莫德仅随整体T细胞抑制而减少其数量,那他珠单抗增加其频率。常用MS疗法对该致病T细胞亚群影响差异显著。
要点
- MS患者CD20+ T细胞呈促炎致病表型。
- 抗CD20治疗几乎清除CD20+ T细胞。
- 不同MS疗法对CD20+ T细胞影响差异显著。
核心结论
- MS患者CD20+ T细胞具促炎表型和致病潜能。
- 抗CD20治疗几乎清除CD20+ T细胞,可能解释其广泛疗效。
- 常用MS疗法对该促炎T细胞亚群影响呈意外差异化。
研究设计与样本
- 研究多发性硬化患者中CD20+ T细胞的表型及不同MS治疗对其影响。
主要发现
- MS患者CD20+ T细胞显示独特促炎表型并具致病特性。
- 抗CD20治疗几乎清除CD20+ T细胞。
- 富马酸二甲酯抑制分化CD20+ T细胞活性。
- 芬戈莫德仅作为整体T细胞抑制的一部分降低CD20+ T细胞数量。
- 那他珠单抗增加CD20+效应T细胞频率。
临床怎么用
- 选择MS疗法时需考虑其对促炎CD20+ T细胞的差异化影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The frequency of CD20+ T cells was reported to be increased in several inflammatory conditions. We report that in patients with multiple sclerosis (MS), CD20+ T cells display a distinct proinflammatory phenotype with pathogenic properties. Anti-CD20 treatment virtually extinguished CD20+ T cells, which might explain its broad effectiveness. Dimethyl fumarate dampened activity of differentiated CD20+ T cells, whereas fingolimod reduced their abundance only as part of its overall T cell suppressive capacity. Natalizumab increased the frequency of CD20+ effector T cells. Widely used MS therapeutics affect this proinflammatory T cell subset with assumed pathogenic potential in a surprisingly differential manner. ANN NEUROL 2021 ANN NEUROL 2021;90:834-839.
引用
- Quendt C, Ochs J, Häusser-Kinzel S, et al. Proinflammatory CD20+ T Cells are Differentially Affected by Multiple Sclerosis Therapeutics. Ann Neurol. 2021. PMID: 34516013. doi:10.1002/ana.26216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。